Oncology

Opdivo shows extended overall survival and fewer adverse events in patients with RCC compared with Afinitor.

Patients with a family history of Lynch syndrome should be presented the option of risk prediction modeling.

Clostridium sporogenes bacteria able to eradicate colon cancer tumor cells.

Top news of the week in cancer drug development.

Osimertinib (Tagrisso) is a once daily tablet for patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

Hormone treatment may prove to be effective alternative option for patients with invasive lobular carcinoma.

Patients with cancer see a decline in employment, hours worked, individual income, and total family income following diagnosis.

Combination of Cotellic and Zelboraf shows superior overall and progression free survival in melanoma treatment.

Newly discovered pathway may prove effective target for treatment of triple-negative breast cancer.

Micro RNA based blood test may be used with imaging features to accurately predict disease severity.

Benefits of Plavix found to outweigh potential adverse events.

Recent news in cancer drug development.

People living in poorer areas less likely to receive screening.

Terms like revolutionary or miracle cause confusion for readers.

Intensity modulated radiation therapy shows less intense lung toxicity for more tolerable chemotherapy.

There are currently no approved treatments for tenosynovial giant cell tumors.

Cancer microenvironment may hold the key to increasing immunotherapy drug efficacy.

With the high volume of cancer drugs available, determining the most effective combination is a significant hurdle.

Combination of everolimus and small molecule compound significantly reduces viability of cancer cells.

Research shows cells are unable to divide and invade at the same time.

Top news of the week in cancer drug development.

Immunosuppressive drug linked to central nervous system lymphoma in solid organ transplant patients.

Rhabdomyosarcoma is the most common soft tissue sarcoma in children.

Ligand-guided protein cages kill more than 70 percent of lung cancer cells during testing.

Study may lead to enhanced efficacy of breast cancer drugs.

Blood test offers insight into how well a drug is working during the course of cancer treatment.

T-VEC is a first-in-class immunotherapy for unresectable cutaneous, subcutaneous, and nodal lesions in advanced melanoma.

Malaria protein is able to attack more than 90 percent of all tumor types.

Non-Hispanic whites more likely to be diagnosed with less advanced stages of breast cancer.

Twice-daily niacin pill for 12-months reduced the incidence of new non-melanoma skin cancers.